Jiangsu Jibeier Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 2.98%

Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has an Asset Resilience Ratio of 2.98% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥81.09 Million
≈ $11.87 Million USD Cash + Short-term Investments

Total Assets

CN¥2.72 Billion
≈ $398.43 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Jiangsu Jibeier Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check Jiangsu Jibeier Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Jibeier Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688566 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥81.09 Million 2.98%
Total Liquid Assets CN¥81.09 Million 2.98%

Asset Resilience Insights

  • Limited Liquidity: Jiangsu Jibeier Pharmaceutical Co Ltd maintains only 2.98% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Jibeier Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Jibeier Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Jiangsu Jibeier Pharmaceutical Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Jibeier Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 1.36% CN¥37.03 Million
≈ $5.42 Million
CN¥2.72 Billion
≈ $397.60 Million
-0.85pp
2024-12-31 2.22% CN¥56.00 Million
≈ $8.19 Million
CN¥2.53 Billion
≈ $369.86 Million
+0.63pp
2023-12-31 1.58% CN¥35.00 Million
≈ $5.12 Million
CN¥2.21 Billion
≈ $323.34 Million
-3.00pp
2022-12-31 4.58% CN¥90.00 Million
≈ $13.17 Million
CN¥1.96 Billion
≈ $287.48 Million
-6.42pp
2021-12-31 11.00% CN¥200.00 Million
≈ $29.27 Million
CN¥1.82 Billion
≈ $266.13 Million
--
pp = percentage points

About Jiangsu Jibeier Pharmaceutical Co Ltd

SHG:688566 China Drug Manufacturers - Specialty & Generic
Market Cap
$716.44 Million
CN¥4.90 Billion CNY
Market Cap Rank
#10421 Global
#2781 in China
Share Price
CN¥24.55
Change (1 day)
-1.29%
52-Week Range
CN¥23.10 - CN¥42.20
All Time High
CN¥51.60
About

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more